These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 1151770

  • 1. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM, Chinn LJ, Pedrera HA, Krupnick MI, Suleymanov OD.
    J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mexrenoate potassium: a steroidal aldosterone antagonist and antihypertensive.
    Hofmann LM, Weier RM, Suleymanov OD, Pedrera HA.
    J Pharmacol Exp Ther; 1977 Jun; 201(3):762-8. PubMed ID: 864608
    [Abstract] [Full Text] [Related]

  • 4. Azolimine: a nonsteroidal antagonist of the effects of mineralocorticoids on renal electrolyte excretion.
    Gussin RZ, Ronsberg MA, Stokey EH, Cummings JR.
    J Pharmacol Exp Ther; 1975 Oct; 195(1):8-15. PubMed ID: 1181406
    [Abstract] [Full Text] [Related]

  • 5. Relative potency of prorenoate and spironolactone in normal man.
    Ramsay L, Harrison I, Shelton J, Tidd M.
    Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Aldosterone antagonism studies in the rhesus monkey.
    Hofmann LM, Pedrera HA, Suleymamov OD.
    J Pharmacol Exp Ther; 1977 Jul; 202(1):216-20. PubMed ID: 406381
    [Abstract] [Full Text] [Related]

  • 11. Effect of aldosterone antagonists on mineralocorticoid synthesis in vitro. Inhibition of aldosterone production by prorenoate-K.
    Netchitailo P, Delarue C, Perroteau I, Jegou S, Tonon MC, Leroux P, Leboulenger F, Kusmierek MC, Capron MH, Vaudry H.
    Eur J Pharmacol; 1982 Feb 05; 77(4):243-9. PubMed ID: 6277668
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Changes in lymphocytes caused by aldosterone and a spironolactone derivative. Animal experiments and clinical studies].
    Liebich HG, Mertin J, Seifert J.
    Fortschr Med; 1982 Nov 04; 100(41):1922-5. PubMed ID: 7152425
    [Abstract] [Full Text] [Related]

  • 15. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects.
    Ramsay LE, Shelton JR, Tidd MJ.
    Br J Clin Pharmacol; 1976 Jun 04; 3(3):475-82. PubMed ID: 788750
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Aldosterone receptor blockade inhibits increased furosemide-sensitive sodium reabsorption in rats with liver cirrhosis.
    Jonassen TE, Petersen JS, Sørensen AM, Andreasen F, Christensen S.
    J Pharmacol Exp Ther; 1998 Dec 04; 287(3):931-6. PubMed ID: 9864275
    [Abstract] [Full Text] [Related]

  • 18. [Steroid spirolactones--antagonists of mineralocorticoids].
    Linèt O.
    Cesk Farm; 1969 Jun 04; 18(4):218-26. PubMed ID: 4895579
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The renal action of spirorenone and other 6 beta,7 beta; 15 beta,16 beta-dimethylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
    Casals-Stenzel J, Buse M, Wambach G, Losert W.
    Arzneimittelforschung; 1984 Jun 04; 34(3):241-6. PubMed ID: 6329237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.